React4life
React4Life Srl is a Genoa-based biotech company developing the MIVO® millifluidic organ-on-chip platform and 3D-flowGel hydrogel for predictive 3D in vitro drug testing. It serves pharmaceutical, biotech, dermocosmetics, nutraceutical, and academic customers via direct sales, custom assay services, and marketplace partners.
- Company typePrivate
- Founded2017
- HeadquartersGenoa, Italy
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What React4life does
React4Life Srl is a privately held Italian biotech company founded in 2017 by Dr. Silvia Scaglione, headquartered in Genoa. It develops and commercializes the MIVO® (Millifluidic Vessel Organ) organ-on-chip platform, a patented technology that combines clinically relevant 3D tissue size with independently controlled millifluidic flow environments for in vitro drug discovery, toxicity testing, and translational research. The platform includes MIVO® Single Flow and Double Flow chamber kits, the 3D-flowGel ready-to-use hydrogel, and the TOKYO high-throughput fluidic module with 24 parallel lines, supporting applications in cancer and immunology, gut/nutraceuticals, dermocosmetics and medical devices, and biotech/pharmaceutical development. A multi-organ Cancer-Liver-on-Chip configuration and integrated custom assay services extend the platform toward combination efficacy and hepatoxicity studies.
React4Life monetizes through a mix of hardware sales (MIVO® chamber kits, 3D-flowGel, TOKYO module), custom cell-based assay services, and research-use licensing, with pricing handled via quote requests rather than public list prices. The go-to-market combines direct enterprise field sales with marketplace distribution through Scientist.com and Skinobs, supplemented by a heavy content and event presence — webinars, workshops, publications, and industry conference participation — targeting pharma, biotech, dermocosmetics, nutraceutical, and academic customers. Reported performance metrics include 92–95% concordance with clinical drug responses using patient-derived samples and reproducible results with sub-2% standard deviations in dermal absorption assays.
The company is founder-led, with Dr. Scaglione as Chief Scientist and Maurizio Aiello as CEO, holds 7 patents tied to the founder and the company, and has earned recognition including the 2023 CPHI Award, the EU Innovation Radar Award for Best Health Technology, the 2021 Gamma Donna Innovative Start-up Award, and a 2024 European Innovation Council Ambassador nomination. In February 2026 it became a founding member of IAMPS, the European industry association for microphysiological systems providers. Revenue and headcount figures are not publicly disclosed; team size is reported at 1–10 employees.
React4life firmographics
Firmographics- Name
- React4life
- Legal name
- React4Life
- Website
- https://react4life.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- React4Life Srl is a Genoa-based biotech company developing the MIVO® millifluidic organ-on-chip platform and 3D-flowGel hydrogel for predictive 3D in vitro drug testing. It serves pharmaceutical, biotech, dermocosmetics, nutraceutical, and academic customers via direct sales, custom assay services, and marketplace partners.
- Ownership category
- akta.pro rank
React4life industry classification
Industry- Product category
- Organ-on-Chip Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)
Keywords
Where React4life is headquartered
LocationHeadquarters
- HQ city
- Genoa
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
React4life business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- MIVO® Hardware Sales: Sale of MIVO® organ-on-chip devices including Single Flow Box (12 MIVO® chambers, 12 single flow lids) and Double Flow Box (12 MIVO® chambers, 12 double flow lids). Devices are sterile and individually blistered for quick and easy use.
- Cell-based Assay Services: Expert R&D team collaborates with customers to design and develop tailored assays. Testing services provide more predictive results with high accuracy and reliability, delivering fast and precise data.
- 3D-flowGel Sales: Sale of 3D-flowGel 3D cell culture matrix product for in vitro cell culture applications.
- Technology Licensing: The company offers technology licensing through terms and conditions for 'Supply of Products and Services – Research Use', indicating licensing arrangements for their proprietary technology.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom quote-based pricing for MIVO® products and services |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
React4life product offering
Product offeringCore offering
React4life develops and manufactures the patented MIVO® (Millifluidic Vessel Organ) organ-on-chip platform, a hardware system that combines clinically relevant 3D tissue models with independently controlled millifluidic flow environments for drug discovery and translational research. The company sells MIVO Single Flow and Double Flow device boxes, the 3D-flowGel hydrogel consumable, and the high-throughput TOKYO fluidic module, and complements these with custom cell-based assay development services for biotech, pharmaceutical, dermocosmetics, and nutraceutical clients.
Product overview
React4Life offers a platform-based product ecosystem centered on the MIVO® millifluidic organ-on-chip technology. The core MIVO® platform is available in Single Flow and Double Flow configurations, combined with 3D-flowGel hydrogel for 3D cell culture. The platform serves four application divisions: Cancer & Immunology (Cancer-on-Chip), Nutraceuticals Food & Feed (Gut-on-Chip), Dermocosmetics Medical Device (Skin-on-Chip), and Biotech Pharmaceutical. Supporting services include custom assay development and scientific support, with resources including publications, workshops, webinars, and application notes documenting research applications.
Differentiator
Problem solved
Functional benefit
Brands
- MIVO®: Proprietary organ-on-chip technology platform combining clinically relevant tissue size with independent millifluidic environments for drug discovery and toxicity testing.
- 3D-flowGel
- TOKYO
Products and services
- MIVO Single Flow
Quantifiable outcome
- 92-95% concordance with clinical drug responses vs. conventional 2D cultures
- +4 more outcomes
Companies that use React4life
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles4 records
React4life technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature5 records
React4life partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- Industry Alliance for Microphysiological Systems (IAMPS)coreReact4Life is a founding member of IAMPS, the world's first industry association dedicated to representing microphysiological systems providers across Europe. The association aims to increase regulatory acceptance of MPS data, create data-sharing platforms, and advance device standardization. Expected to become operational in Q2 2026.
- AlveolixcoreFellow founding member of IAMPS industry alliance, headquartered in Switzerland. Collaborates with React4Life on regulatory acceptance and standardization of MPS technologies.
- BiomimXcoreFellow founding member of IAMPS industry alliance from Italy. Part of the nine founding members working to advance microphysiological systems in Europe.
- ChironcoreFellow founding member of IAMPS industry alliance from Italy. Contributing to regulatory acceptance and standardization efforts.
- Dynamic42coreFellow founding member of IAMPS industry alliance from Germany. Part of the nine founding companies advancing MPS technologies.
- InSpherocoreFellow founding member of IAMPS industry alliance from Switzerland. Contributing to data-sharing platforms and device standardization.
- MIMETAScoreFellow founding member of IAMPS industry alliance from the Netherlands. Partnered with React4Life on regulatory acceptance and MPS data standards.
- NETRIcoreFellow founding member of IAMPS industry alliance from France. Part of the nine founding members advancing organ-on-chip technologies.
- TissUsecoreFellow founding member of IAMPS industry alliance from Germany. Partnered with React4Life in this industry association for microphysiological systems.
- PromoCellminorJoint webinar collaboration with PromoCell on advancing reproducible 3D cancer models into dynamic cancer-on-chip systems. PromoCell provides cancer media toolbox supporting CSC-driven growth across multiple cancer types.
- Prodeco PharmaminorStrategic collaboration between React4Life and Prodeco Pharma to evaluate protective and reparative effects of GSE Reflusolve Rapid using MIVO® esophagus-on-chip platform in GERD research.
Scale indicators6 records
Recent moves5 records
Expansion highlights4 records
React4life competitors and assessment
Company assessmentDirect peers
- Alveolix: Swiss lung-on-chip company with alveolar and airway models for respiratory drug testing. Direct peer in MPS and IAMPS co-founding member serving pharma and inhaled therapeutics customers.
- MIMETAS: Dutch organ-on-chip company developing the OrganoPlate platform for high-throughput 3D tissue models. Direct peer offering competing organ-on-chip products to pharma R&D, and co-founding member of IAMPS with React4Life.
- InSphero: Swiss 3D cell culture and organ-on-chip company serving pharma toxicology and disease modeling. Direct peer in microphysiological systems and fellow IAMPS founding member, targeting the same biotech and pharma customers.
- TissUse: German multi-organ-on-chip company with a HUMIMIC platform for connected organ models. Direct peer in MPS/multi-organ-chip, and fellow IAMPS founding member addressing the same pharma and cosmetics testing customers.
- Emulate: US-based organ-on-chip company and one of the most capitalized players in the space, with the Emulate platform serving pharma R&D. Direct peer with deeper commercial scale and broader enterprise penetration.
- CN Bio: UK organ-on-chip company offering the PhysioMimix platform for drug discovery and toxicology. Direct peer targeting the same pharma ADME/Tox and disease modeling applications as React4Life.
- Dynamic42: German organ-on-chip company developing immune and infection models using microfluidic chip technology. Direct peer and IAMPS founding member addressing pharma and academic customers.
- NETRI: French organ-on-chip company specializing in neuro-on-chip and microfluidic devices for pharma and cosmetics. Direct peer and IAMPS founding member targeting adjacent applications to React4Life's platform.
- BiomimX: Italian organ-on-chip company developing multi-organ and disease models. Direct peer in MPS, fellow Italian company, and IAMPS founding member competing for similar European pharma and academic customers.
- SynVivo (Nortis): US organ-on-chip company providing microfluidic tissue models for drug development and toxicity testing. Direct peer offering competing OoC hardware and services to pharma researchers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
React4life social profiles
Digital presenceReact4life financial estimates
Financial estimateRevenue estimate
Valuation estimate
React4life leadership team
Management profileNumber of profiles
Profiles2 records
React4life funding detail
Funding detailFunding overview
Funding rounds9 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
React4life M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about React4life
What does React4life do?
React4life develops and manufactures the patented MIVO® (Millifluidic Vessel Organ) organ-on-chip platform, a hardware system that combines clinically relevant 3D tissue models with independently controlled millifluidic flow environments for drug discovery and translational research. The company sells MIVO Single Flow and Double Flow device boxes, the 3D-flowGel hydrogel consumable, and the high-throughput TOKYO fluidic module, and complements these with custom cell-based assay development services for biotech, pharmaceutical, dermocosmetics, and nutraceutical clients.
Is React4life a public or private company?
React4life is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was React4life founded?
React4life was founded in 2017. It employs 1 to 10 people.
Where is React4life based?
React4life is headquartered in Genoa, Italy, in the Europe region.
How does React4life make money?
Four revenue lines are on record. MIVO® Hardware Sales are the primary driver. The others are cell-based Assay Services, 3D-flowGel Sales and technology Licensing.
Who are React4life's main competitors?
Direct peers on record are Alveolix, MIMETAS, InSphero, TissUse, Emulate, CN Bio, Dynamic42, NETRI, BiomimX and SynVivo (Nortis).
Does React4life have an API?
No public API is recorded for React4life.
What industry is React4life in?
React4life's product category is Organ-on-Chip Technology. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 541714 and its SIC code is 8731.